GlassScriptPhysician profile
Mary K Jabin
NPI 1548263866
$2,102.10
in general payments reported to CMS, 2019-2025
23 companies · $62.27 in 2025
The $62.27 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $265 · 2021: $119 · 2022: $463 · 2023: $581 · 2024: $293 · 2025: $62.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.06 | 2019-2023 | |
| Astellas Pharma US INC | $393.15 | 2023-2025 | Veozah, Myrbetriq |
| Gynesonics, INC. | $337.34 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Pfizer INC. | $149.40 | 2020-2023 | |
| Exeltis, USA INC. | $95.41 | 2021-2024 | Slynd |
| Channel Medsystems, INC. | $91.27 | 2023 | |
| Aspira Women'S Health INC | $88.96 | 2023-2024 | Ova1 |
| Therapeuticsmd, INC. | $63.05 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $61.58 | 2019 | |
| Sage Therapeutics, LLC | $46.85 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $40.07 | 2019-2023 | Paragard T 380a |
| Organon LLC | $31.94 | 2023-2024 | Nexplanon |
| Amgen INC. | $30.70 | 2020-2023 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $30.13 | 2023-2024 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $29.45 | 2019-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $25.00 | 2020 | |
| Roche Diagnostics Corporation | $23.78 | 2019 | |
| Agile Therapeutics, INC. | $21.88 | 2023 | Twirla |
| Myovant Sciences INC. | $17.85 | 2022 | |
| Mylan Pharmaceuticals INC. | $17.77 | 2021 | |
| Mayne Pharma Commercial LLC | $16.20 | 2025 | |
| Vertical Pharmaceuticals, LLC | $14.80 | 2020 | |
| Hologic Sales and Service, LLC | $14.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Jabin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.